MedTrace Logo

AssesSment of Early-deteCtion basEd oN liquiD Biopsy in GASTRIC Cancer, ASCEND-Gastric

NCT05224596 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 498

Last updated 2022-02-28

No results posted yet for this study

Summary

ASCEND-Gastric is a prospective, multi-omics, observational study aimed at detecting gastric cancer by combined assays for serum protein markers, deep sequencing of cell-free DNA (cfDNA), circulating tumor DNA (ctDNA) mutation and circulating RNA. The study will enroll 498 participants, including 128 patients with benign gastric diseases and 370 patients with gastric cancer.

Conditions

Interventions

DIAGNOSTIC_TEST

Blood draw and blood-based biomarkers analyses

blood-based biomarkers analyses

Sponsors & Collaborators

  • Guangzhou Burning Rock Bioengineering Ltd.

    collaborator INDUSTRY

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Yihong Sun Sun, MD · Zhongshan Hospital, Fudan University,China

  • Xuefei Wang, MD · Zhongshan Hospital, Fudan University,China

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-18
Primary Completion
2022-05-30
Completion
2022-09-22

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05224596 on ClinicalTrials.gov